Memphis Pharmaceuticals & Chemical Industries (EGX:MPCI)

EGX:MPCI Cash Flow Statement

Financials in millions EGP. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Net Income	376.65	191.46	90.44	74.09	41.81	17.41
Depreciation & Amortization	20.91	12.18	-	-	-	9.68
Other Operating Activities	-379.25	-20.43	-32.5	-37.62	-38.33	-30.27
Operating Cash Flow	18.31	183.21	57.94	36.47	3.47	-3.18
Operating Cash Flow Growth	-96.57%	216.20%	58.88%	950.33%	-	-
Capital Expenditures	-31.46	-24.37	-11.45	-12.92	-2.07	-0.8
Other Investing Activities	99.51	54.97	10.87	7.69	4.68	2.53
Investing Cash Flow	68.04	30.59	-0.58	-5.24	2.62	1.73
Long-Term Debt Issued	-	174.7	2.34	-	-	-
Net Debt Issued (Repaid)	-36.48	174.7	2.34	-	-	-
Common Dividends Paid	-18.76	-12.17	-	-	-0.25	-
Financing Cash Flow	-55.24	162.53	2.34	-	-0.25	-
Miscellaneous Cash Flow Adjustments	-0	-0	-	-	-	-0
Net Cash Flow	31.11	376.33	59.7	31.23	5.84	-1.45
Free Cash Flow	-13.15	158.83	46.49	23.55	1.4	-3.98
Free Cash Flow Growth	-	241.66%	97.45%	1578.00%	-	-
Free Cash Flow Margin	-1.07%	18.22%	7.00%	4.27%	0.27%	-0.81%
Free Cash Flow Per Share	-2.34	28.24	8.27	4.19	-	-0.71
Cash Interest Paid	23.21	14.26	36.79	-	-	0
Cash Income Tax Paid	58.83	24.84	22.41	7.04	9.38	7.01
Levered Free Cash Flow	74.06	279.99	36.76	-5.31	-1.42	33.2
Unlevered Free Cash Flow	82.97	288.9	36.76	-5.31	-1.42	33.2
Change in Net Working Capital	141.43	-185.17	11.72	35.54	20.69	-17.06

Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.